GeneTether Therapeutics Inc.

GTTX

CA37187D1087

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 10:45:02 2024-05-21 EDT			5-day change	1st Jan Change
0.025 ^CAD	-54.55%		-54.55%	-37.50%

03-30	5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	CI
03-29	GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

GeneTether Therapeutics Inc. has filed an IPO.

November 04, 2021 at 12:00 am

GeneTether Therapeutics Inc. has filed an IPO.

Security Name: Units
Security Type: Equity/Derivative Unit

Transaction Features: Rule 144A

Latest news about GeneTether Therapeutics Inc.

5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	03-29	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-27	CI
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2023.	23-09-29	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2023.	23-03-29	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-25	CI
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2022.	22-09-29	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-24	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-26	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-28	CI
GeneTether Therapeutics Inc. has completed an IPO.	22-03-29	CI
GeneTether Therapeutics Inc. announced that it has received CAD 4.5 million in funding	22-03-28	CI
GeneTether Therapeutics Inc. announced a financing transaction	22-03-21	CI
GeneTether Therapeutics Inc. has filed an IPO.	21-11-04	CI
GeneTether Therapeutics Inc. Auditor Raises 'Going Concern' Doubt	21-11-03	CI
GeneTether Therapeutics Inc. Auditor Raises 'Going Concern' Doubt	21-11-03	CI

Chart GeneTether Therapeutics Inc.

Duration

Period

More charts

GeneTether Therapeutics Inc. is a Canada-based genetic medicines company focused on creating gene editing therapies based on its proprietary GeneTether platform. The Company's platform technology uses a proprietary method to tether donor deoxyribonucleic acid (DNA) templates to the genome editing complex, making the template readily available for use during the genome editing repair stage. By positioning a donor DNA template directly at the site of a double strand break, the Company's GeneTether platform drives the DNA repair process towards homology-directed repair (HDR), a cellular repair mechanism that incorporates the genetic information of a DNA template. It is building a discovery pipeline focused on the treatment of rare, monogenic diseases of the kidney and the skin. The Company's GeneTether platform may also allow for high fidelity engineering of cells to permanently deliver the therapeutic proteins necessary to treat certain genetic diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENETETHER THERAPEUTICS INC.	-37.50%	710K
MODERNA, INC.	+54.05%	63.85B
IQVIA HOLDINGS INC.	-2.02%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B
BIO-TECHNE CORPORATION	+2.89%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.40%	12.11B
MEDPACE HOLDINGS, INC.	+27.49%	12.07B